Finance

Lists
002773:SHE
Chengdu Kanghong Pharma Grp Co Ltd
19,44 CN¥
-1,92%
(-0,38) 1D
16-окт., 15:04:09 GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 002773...
Open
20,34 CN¥
High
20,34 CN¥
Low
19,30 CN¥
Mkt. cap
18,61 млд
Avg. vol.
7,30 млн
Volume
6,59 млн
Dividend
3,60%
Quarterly dividend
0,17 CN¥
Ex-dividend date
2026-ж., 9-июн.
P/E ratio
18,00
52-wk high
36,10 CN¥
52-wk low
18,62 CN¥
EPS
1,08 CN¥
Shares outstanding
921,33 млн
No. of employees
4 миң
Open
20,34 CN¥
High
20,34 CN¥
Low
19,30 CN¥
Mkt. cap
18,61 млд
Avg. vol.
7,30 млн
Volume
6,59 млн
Dividend
3,60%
Quarterly dividend
0,17 CN¥
Ex-dividend date
2026-ж., 9-июн.
P/E ratio
18,00
52-wk high
36,10 CN¥
52-wk low
18,62 CN¥
EPS
1,08 CN¥
Shares outstanding
921,33 млн
No. of employees
4 миң
News stories
From web sources and news partners
Profile
Chengdu Kanghong Pharmaceutical Group Co., Ltd. is a publicly traded pharmaceutical company based in the province of Sichuan, China. It was founded in 1996 and researches, develops, manufactures, and distributes medicines for ophthalmic, central nervous, digestive and endocrine systems. The company is listed on the Shenzhen stock exchange with a market capitalization at around $6 billion. As of May 2021, the company had 18 drugs on the market including Lumitin. Additional products include Songling xuemaikang capsules, Keluoxin capsules, Xinluona, Bolexin and Bosiqing, Yitaning, Shugan Jieyu, Danshu, and Yiqing. Kanghong also currently has 13 subsidiaries in China, Israel, and the United States. Wikipedia
About Chengdu Kanghong Pharma Grp Co Ltd
CEO-
Employees4,47 миң
Founded1996-ж., 3-окт.
Headquarters-
SectorPharmaceutical industry
Websitecnkh.com
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
1,17 млд
961,27 млн
1,05 млд
1,13 млд
Cost of goods sold
103,16 млн
116,91 млн
118,65 млн
132,03 млн
Cost of revenue
103,16 млн
116,91 млн
118,65 млн
132,03 млн
Research and development expenses
119,54 млн
198,94 млн
86,77 млн
138,57 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
595,28 млн
521,75 млн
478,88 млн
554,55 млн
Operating expense
697,02 млн
764,40 млн
582,81 млн
717,78 млн
Total operating expenses
800,18 млн
881,31 млн
701,46 млн
849,80 млн
Operating income
370,02 млн
79,96 млн
345,02 млн
282,88 млн
Other non operating income
-19,53 млн
19,27 млн
-1,04 млн
-1,54 млн
EBT including unusual items
355,99 млн
147,66 млн
358,51 млн
301,88 млн
EBT excluding unusual items
364,66 млн
135,96 млн
356,39 млн
306,28 млн
Income tax expense
56,73 млн
23,28 млн
55,31 млн
50,13 млн
Effective tax rate
15,94%
15,77%
15,43%
16,61%
Other operating expenses
-17,83 млн
43,89 млн
16,62 млн
23,18 млн
Net income
303,21 млн
130,06 млн
307,48 млн
257,26 млн
Net profit margin
25,91%
13,53%
29,38%
22,71%
Earnings per share
-
-
-
-
Interest and investment income
14,20 млн
36,91 млн
12,63 млн
24,92 млн
Interest expense
-
-
-
-
Net interest expenses
14,20 млн
36,91 млн
12,63 млн
24,92 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
427,31 млн
139,05 млн
404,11 млн
345,15 млн
Gain or loss from assets sale
3,47 миң
-9,78 миң
-
61,06 миң
AI content may include mistakes. Learn more
Google колдонмолору